FeedKind aquaculture feed. (Photo: Calysta)
Calysta partners Nofima for new aquaculture protein trial
Thursday, May 17, 2018, 02:30 (GMT + 9)
Calysta, Inc. intends to conduct large-scale trials in Atlantic salmon using its FeedKind® protein as a means to improve feed efficiency and fish health through a partnership with Nofima.
Calysta pointed out that FeedKind has been shown to improve key nutritional metrics for commercial aquaculture – increased feed efficiency and the maintenance of a healthy digestive tract and immune system.
In addition, the firm stresses it provides the industry with the first scalable alternative protein requiring no wild caught fish or agricultural land, contributing to global food security.
“FeedKind protein is a cost-effective, sustainable feed ingredient for major farmed seafood species including salmon, trout and shrimp,” said Allan LeBlanc, Senior Director and FeedKind Product Manager.
The director also highlighted that the aquaculture industry is actively seeking new solutions to reduce costs associated with biological challenges and environmental impact.
“We are eager to do research on FeedKind as we believe that this may be an example of new protein sources that can contribute to a more sustainable aquaculture,” said Mari Moren, director of research at Nofima.
Moren explained that Feedkind’s effect on salmon will be thoroughly tested at Nofima’s research facilities along with the effects this protein may have on the physicochemical qualities of the feed pellet.
FeedKind is a natural, safe, and sustainable non-animal source of protein approved for sale in the European Union and several Asian countries.
It has been shown to use 77-98 per cent less water and >98 per cent less land than alternative ingredients such as soy or wheat proteins.
In salmon, trout, and shrimp trials, FeedKind has been shown to produce equivalent growth and survival rates when compared to a conventional fishmeal diet. It is approved as an ingredient in organic systems for animal feed in the United Kingdom and EU.
The trials, to be designed by Nofima, will begin in early 2019.